Optical Imaging Scans for Skin Cancer Diagnosis
This study is looking at how well a special optical imaging scan, called quantitative oblique back-illumination microscopy (qOBM), can help doctors find skin cancer in people with skin lesions (unusual growths or spots). qOBM is a gentle procedure that uses red light and doesn't involve cutting the skin. The researchers want to see if qOBM can improve how doctors diagnose skin lesions. You might be able to join if you are 18 or older and have skin lesions. The study will look at how well qOBM can assess skin problems over a period of up to 12 months. The study is currently unclear on its recruitment status and plans to enroll 10 participants.
- Study design
- This is an interventional study with 10 planned participants. Patients will be assigned to one of two groups to undergo qOBM optical imaging scans.
- What's involved
- Participants will undergo a qOBM optical imaging scan. Some may also undergo standard radiation therapy.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, qOBM Clinical Assessment, is measured for up to 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions
At a glance
Conditions
NCT07213154
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Emory University Hospital Midtown
Atlanta, Georgiastudy coordinator listed
Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR · PRINCIPAL_INVESTIGATOR · Emory University Hospital/Winship Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- qOBM Clinical AssessmentUp to 12 months
Assessing the application of quantitative oblique back-illumination microscopy (qOBM) to assess skin pathology. Analysis will be descriptive in nature (e.g., appearance of cells in the epidermis, dermis, and basal junction). Quantitative analysis will include extracting image features such as mean, standard deviation, and kurtosis of the phase values; entropy, fractal dimension, gray level co-occurrence matrix, and other mathematical image features. Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria (Skin) Grade 0. No change over baseline, Grade 1. Follicular, faint or dull erythema/epilation/dry desquamation/decreased sweating, Grade 2. Tender or bright erythema, patchy moist desquamation/moderate edema, Grade 3. Confluent, moist desquamation other than skin folds, pitting edema, Grade 4. Ulceration, hemorrhage, necrosis